Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases.


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
02 04 2020
Historique:
received: 16 12 2019
revised: 17 02 2020
accepted: 05 03 2020
entrez: 4 4 2020
pubmed: 4 4 2020
medline: 21 10 2020
Statut: ppublish

Résumé

Autoimmune diseases are a result of the immune system being misdirected toward its host and have major and increasing unmet clinical needs. In general, present therapies are broadly acting and non-disease specific; consequently, they are associated with numerous side effects. Precise and early intervention strategies are urgently needed. We highlight the challenges, progress, and prospects in achieving these goals.

Identifiants

pubmed: 32243797
pii: S0092-8674(20)30269-5
doi: 10.1016/j.cell.2020.03.007
pii:
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

63-80

Subventions

Organisme : Medical Research Council
ID : MC_UU_00008/3
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100308/Z/12/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests J.R. has received funds to work on autoimmune diseases from Janssen Research & Development, LLC.

Auteurs

Lars Fugger (L)

Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK; Department of Clinical Medicine, Aarhus University Hospital, 8200 N Aarhus, Denmark. Electronic address: lars.fugger@imm.ox.ac.uk.

Lise Torp Jensen (LT)

Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK; Department of Clinical Medicine, Aarhus University Hospital, 8200 N Aarhus, Denmark.

Jamie Rossjohn (J)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia; Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff CF14 4XN, UK. Electronic address: jamie.rossjohn@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH